About us

Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, LSE:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for  Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.


Our mission is to bring breakthrough therapies with the aim of treating Crohn's Disease, COVID-19, Pro-MS and HCC and optimizing health outcomes.


We envision becoming a leader in advancing innovative, best-in-class medicines for patients with life threatening diseases.

Corporate Documents

View our latest investor presentation Investor Presentation April 2021

View our investor report for 2020 Investor Report 2020

Prospectus: Listing on Main Market Tiziana Prospectus: Admission of the Issued Share Capital to the Official List (by way of a Standard Listing under Chapter 14 of the Listing Rules) and to trading on the main market for listed securities of the London Stock Exchange


Tiziana Life Sciences completed the demerger of StemPrinter from the company on October 30th, 2020. It is now expected that the Accustem Shares will have a standard listing on the Official List and be admitted to trading on the London Stock Exchange. The Tiziana Shares will retain their LSE listing but a process is underway to seek admission to the standard segment of the Official List and trading on the London Stock Exchange. It is expected that Accustem Admission will occur during Q1, 2021.

Accustem American Depositary Shares’s (“ADSs”) will be distributed to the eligible holders of Tiziana ADS’s promptly after the Registration Statements described here are declared effective by the U.S. Securities and Exchange Commission (the “Commission”). During the remainder of 2020, Tiziana will proceed to file a registration statement for the new Accustem ordinary shares with the Commission and Accustem will establish a sponsored ADR program with JPMorgan. Accustem and JPMorgan will subsequently file a Form F-6 registration statement with the Commission in order to enable holders of Tiziana ADSs at the close of business (NY time) on the ADS Record Date to receive one ADS, each representing two ordinary shares of Accustem (CUSIP to be determined), for each Tiziana ADS held of record at such time.

 Circular Sent to Shareholders: September 2020

Foralumab mAb 

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’ s and neurodegenerative diseases. We have recently completed two Phase 1 clinical trials: one for progressive MS indication with nasal administration and the other for Crohn’s disease indication, with enteric coated capsules administered orally. Foralumab has demonstrated ability to activate regulatory T cells that systemically circulate to elicit targeted immunomodulation providing therapeutic benefit to patients. 

Tiziana has recently submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival. Foralumab administered alone or co-administered in combination with co-stimulatory molecules, such as an anti-IL-6 receptor monoclonal antibody, an anti-CD28 monoclonal antibody or specific inhibitors of signaling pathways of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), or mammalian target to improve success of CAR-T therapy.

Anti IL-6R mAb

Anti IL-6R is a fully human mAb, which binds to both the membrane-bound and soluble forms of the IL6R and depletes circulating levels of the IL-6 in the blood. Tiziana is accelerating development in Anti IL-6R mAb as a treatment of COVID-19.


Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma. Milciclib, a pan cyclin-dependent kinases (CDK) inhibitor, has demonstrated potent anti-tumor activity as a monotherapy as well as combination therapy. Milciclib is also being used for treatment of recurrent HCC in liver transplant patients in an investigator-initiated clinical trial. The safety and clinical activity of combination treatment of Milciclib with Regorafenib in liver transplant patients with recurrent HCC has been evaluated showing combination treatment was well tolerated with manageable toxicities. Safety and clinical activity data was presented at Virtual ASCO 2020 conference.